Table 2.

Phosphoinositide 3-Kinase Inhibitors in Clinical Trials for Asthma and Chronic Obstructive Pulmonary Disease

Compound	Target	Indication	Clinical Trial Identifier
Idelalisib (CAL-101)	p110δ	Chronic lymphocytic leukemia	FDA and EMA approved, 2014
GSK2269557	p110δ	Asthma	NCT01462617, Phase 1
IPI-145	p110δ/p110γ	Asthma	NCT01653756, Phase 2
RV-1729	p110δ/p110γ	Asthma/COPD	NCT01813084, Phase 1
AQX-1125	SHIP1 activator	COPD	NCT01954628, Phase 2

Definition of abbreviations: COPD, chronic obstructive pulmonary disease; EMA, European Medicines Agency; FDA, U.S. Food and Drug Administration; P110δ, phosphatidylinositol 3-kinase catalytic subunit δ isoform; P110γ, phosphatidylinositol 3-kinase catalytic subunit γ isoform; SHIP, SH2 domain-containing inositol phosphatase.